AngioDynamics, Inc. (ANGO)

AngioDynamics, Inc. (ANGO) Healthcare & Pipeline Overview

AngioDynamics, Inc. specializes in medical devices for vascular and oncology applications, offering solutions like NanoKnife ablation systems and vascular access products. With a focus on minimally invasive procedures, the company serves a global market through direct sales and distributor relationships, facing competition in a dynamic healthcare landscape.

What Is the Investment Thesis for ANGO?

AngioDynamics presents a mixed investment case. The company operates in the growing medical device market, with a focus on minimally invasive procedures, reflected in a 53.5% gross margin. Growth catalysts include expansion of its NanoKnife ablation system and vascular access product lines. However, a negative profit margin of -10.0% raises concerns about profitability. The company's beta of 0.45 suggests lower volatility compared to the broader market. Investors should closely monitor AngioDynamics' ability to improve profitability, manage operating expenses, and capitalize on growth opportunities in the medical device sector. The company's market capitalization is $0.44B. Key value drivers include innovation in ablation technologies and expansion of its distribution network.

Based on FMP financials and quantitative analysis

ANGO Key Highlights

• Market Cap of $534.67M reflects the company's size and investor valuation in the medical device market.
• Gross Margin of 53.5% indicates the company's ability to efficiently produce and sell its medical devices.
• Profit Margin of -10.0% raises concerns about the company's profitability and expense management.
• Beta of 0.45 suggests lower volatility compared to the broader market, potentially appealing to risk-averse investors.
• No Dividend Yield indicates that the company is reinvesting its earnings for growth rather than distributing them to shareholders.

Who Are ANGO's Competitors?

ANGO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ANGO's Key Strengths?

• Specialized product portfolio in vascular and oncology.
• Proprietary NanoKnife ablation technology.
• Established relationships with key healthcare providers.
• Direct sales force and distributor network.

What Are ANGO's Weaknesses?

• Negative profit margin.
• Smaller market capitalization compared to major competitors.
• Dependence on specific product lines.
• Limited geographic diversification.

What Could Drive ANGO Stock Higher?

• New product launches in vascular access and ablation technologies.
• Expansion of NanoKnife clinical applications.
• Strategic partnerships to expand market reach.
• Regulatory approvals for new medical devices.

What Are the Key Risks for ANGO?

• Negative return on equity (-17.6%) — the business is not currently generating profit on shareholder capital.
• Increased competition from larger medical device companies.
• Regulatory compliance and potential product recalls.
• Technological obsolescence.
• Pricing pressures from healthcare providers.
• Negative profit margin impacting financial stability.

What Are the Growth Opportunities for ANGO?

• Expansion of NanoKnife Ablation System: The NanoKnife ablation system represents a significant growth opportunity for AngioDynamics. This system uses irreversible electroporation (IRE) to ablate soft tissues, offering a minimally invasive alternative to traditional surgery. The market for ablation technologies is projected to reach billions of dollars by 2028, driven by the increasing prevalence of cancer and the demand for less invasive treatment options. AngioDynamics can capitalize on this opportunity by expanding the clinical applications of NanoKnife, increasing its market penetration, and developing new versions of the system with enhanced features.
• Growth in Vascular Access Products: AngioDynamics' vascular access product line, which includes PICCs, midline catheters, and implantable ports, represents another significant growth opportunity. The market for vascular access devices is driven by the increasing use of intravenous therapies, such as chemotherapy and antibiotics. AngioDynamics can grow its vascular access business by expanding its product portfolio, increasing its market share, and developing new products with advanced features, such as antimicrobial coatings and improved biocompatibility. The global vascular access market is expected to grow steadily through 2026.
• Strategic Acquisitions: AngioDynamics can pursue strategic acquisitions to expand its product portfolio, enter new markets, and gain access to new technologies. The medical device industry is characterized by consolidation, with larger companies acquiring smaller, innovative companies to drive growth. AngioDynamics can target companies with complementary product lines or technologies, such as companies specializing in surgical instruments, diagnostic imaging, or drug delivery. Successful acquisitions can accelerate AngioDynamics' growth and enhance its competitive position.
• International Expansion: AngioDynamics can expand its international presence to tap into new markets and diversify its revenue streams. The medical device market is growing rapidly in emerging economies, such as China, India, and Brazil, driven by increasing healthcare spending and improving access to healthcare services. AngioDynamics can enter these markets through partnerships, distribution agreements, or direct sales operations. International expansion can significantly increase AngioDynamics' revenue and profitability.
• Development of New Products: AngioDynamics can invest in research and development to create new and innovative medical devices that address unmet clinical needs. The medical device industry is characterized by rapid technological advancements, and companies that can develop and commercialize new products have a significant competitive advantage. AngioDynamics can focus on developing products that improve patient outcomes, reduce healthcare costs, and simplify surgical procedures. New product development can drive long-term growth and enhance AngioDynamics' reputation as an innovator.

What Opportunities Does ANGO Have?

• Expansion of NanoKnife applications.
• Growth in vascular access market.
• Strategic acquisitions to expand product portfolio.
• International expansion in emerging markets.

What Threats Does ANGO Face?

• Intense competition from larger medical device companies.
• Technological obsolescence.
• Regulatory changes and compliance requirements.
• Pricing pressures from healthcare providers.

What Are ANGO's Competitive Advantages?

• Proprietary ablation technologies (e.g., NanoKnife).
• Established relationships with healthcare providers.
• Specialized product portfolio in niche markets.
• Strong brand reputation for quality and innovation.

What Does ANGO Do?

Founded in 1988 and headquartered in Latham, New York, AngioDynamics, Inc. designs, manufactures, and markets a range of medical devices for use in minimally invasive procedures. The company's initial focus was on developing innovative solutions for vascular access, and it has since expanded its portfolio to include products for peripheral vascular disease, oncology, and surgery. AngioDynamics' product lines include NanoKnife ablation systems, used for the surgical ablation of soft tissues; Solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. The company also offers a variety of vascular access products, such as peripherally inserted central catheters (PICCs), midline catheters, and implantable ports, used for delivering short-term drug therapies. AngioDynamics sells and markets its products directly to healthcare providers, including interventional radiologists, interventional cardiologists, vascular surgeons, and oncologists, as well as through distributor relationships, serving both the United States and international markets. The company's evolution has been marked by strategic acquisitions and product development initiatives aimed at expanding its market reach and addressing unmet clinical needs in the minimally invasive surgery space. AngioDynamics continues to innovate and adapt to the changing healthcare landscape, focusing on providing solutions that improve patient outcomes and reduce healthcare costs.

What Products and Services Does ANGO Offer?

• Designs, manufactures, and sells medical devices.
• Offers solutions for peripheral vascular disease.
• Provides vascular access products like PICCs and ports.
• Develops ablation systems for oncology and surgery.
• Markets products to interventional radiologists and cardiologists.
• Sells products directly and through distributors.
• Offers devices for thrombus management and atherectomy.

How Does ANGO Make Money?

• Develops and manufactures medical devices in-house.
• Sells products directly to hospitals and clinics.
• Utilizes distributor relationships to expand market reach.
• Generates revenue through product sales and related services.

What Industry Does ANGO Operate In?

AngioDynamics operates within the medical device industry, which is characterized by continuous innovation, stringent regulatory requirements, and intense competition. The global medical device market is projected to reach hundreds of billions of dollars by 2026, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in minimally invasive procedures. AngioDynamics competes with larger, more established medical device companies, as well as smaller, specialized players. The company's success depends on its ability to develop and commercialize innovative products, maintain regulatory compliance, and effectively market its products to healthcare providers. Key trends in the industry include the increasing adoption of minimally invasive surgical techniques, the growing demand for personalized medicine, and the rise of digital health technologies.

Who Are ANGO's Key Customers?

• Interventional radiologists
• Interventional cardiologists
• Vascular surgeons
• Oncologists
• Critical care nurses

Net buyingInsider Activity

The most recent 12 insider filings for AngioDynamics, Inc. break down as 9 sales and 3 purchases. On net that is roughly 11K shares acquired (about $152K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: AngioDynamics, Inc.

Revenue for AngioDynamics, Inc. came in at $78.4M during Q1 2026, a 1.3% contraction versus the preceding quarter. The company recorded a net loss of $8.1M, with diluted EPS of $-0.19. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ANGO averaged $-0.19 in diluted EPS.

ANGO Valuation & Market Position

With a $534.67M market cap, AngioDynamics, Inc. sits in the small-cap segment of the market. Relative to its peer group, ANGO's quantitative score of 36/100 is below the peer average of 78/100.

ROE -18%Key Financial Metrics

Return on equity for AngioDynamics, Inc. stands at -17.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.35 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

AngioDynamics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.53 places it in the grey zone, a middle ground that warrants monitoring.

FY2026 estForward Outlook

Wall Street analysts project AngioDynamics, Inc. revenue of about $314.1M for fiscal 2026, with EPS near $-0.16. The estimate reflects 3 contributing analysts.

Company Profile

AngioDynamics, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Latham, US. The company is led by CEO James C. Clemmer. ANGO has traded publicly since 2004.

ANGO Financials

ANGO Latest News

ANGO Analyst Consensus

ANGO MoonshotScore

Latest AngioDynamics, Inc. Analysis

AngioDynamics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources